Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:ATHE NASDAQ:IMRX NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$8.44+2.7%$7.10$5.47▼$11.99$170.52MN/A55,980 shs41,064 shsATHEAlterity Therapeutics$4.94-1.6%$4.82$1.00▼$7.00$44.53M0.6718,408 shs13,939 shsIMRXImmuneering$5.75+2.7%$3.90$1.10▼$6.18$203.39M0.37867,494 shs376,252 shsNVCTNuvectis Pharma$6.56+0.5%$7.26$4.44▼$11.80$166.23M-0.26111,299 shs35,939 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+2.68%+0.96%+16.09%-25.70%+5.76%ATHEAlterity Therapeutics-1.59%-1.59%-4.45%+10.76%+250.35%IMRXImmuneering+2.68%+17.59%+58.40%+242.26%+408.85%NVCTNuvectis Pharma+0.46%-4.51%-13.11%-28.46%-6.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATHEAlterity Therapeutics2.5887 of 5 stars3.35.00.00.02.21.70.0IMRXImmuneering3.4625 of 5 stars3.34.00.00.01.85.00.6NVCTNuvectis Pharma3.4513 of 5 stars3.53.00.00.02.25.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.33140.92% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00142.91% UpsideIMRXImmuneering 2.60Moderate Buy$13.00126.09% UpsideNVCTNuvectis Pharma 3.00Buy$15.33133.74% UpsideCurrent Analyst Ratings BreakdownLatest ATHE, IMRX, NVCT, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.008/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.008/25/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.008/18/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/4/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.006/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/3/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A($0.13) per shareN/AATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AIMRXImmuneeringN/AN/AN/AN/A$0.80 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-281.83%N/AATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/AN/AIMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)Latest ATHE, IMRX, NVCT, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.730.73ATHEAlterity TherapeuticsN/A3.84N/AIMRXImmuneeringN/A3.703.70NVCTNuvectis PharmaN/A2.662.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AATHEAlterity Therapeutics2.14%IMRXImmuneering67.65%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%ATHEAlterity Therapeutics38.80%IMRXImmuneering22.90%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1020.75 million6.36 millionN/AATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableIMRXImmuneering6036.32 million28.00 millionNot OptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableATHE, IMRX, NVCT, and ACTU HeadlinesRecent News About These CompaniesNuvectis Pharma, Inc.August 26, 2025 | cnn.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateAugust 18, 2025 | marketbeat.comQ3 EPS Estimates for Nuvectis Pharma Lifted by HC WainwrightAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Nuvectis Pharma Boosted by Roth CapitalAugust 16, 2025 | marketbeat.comNuvectis Pharma FY2028 EPS Forecast Raised by Roth CapitalAugust 15, 2025 | marketbeat.comNuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 12, 2025 | finanznachrichten.deNuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 11, 2025 | globenewswire.comRoth Capital Forecasts Lower Earnings for Nuvectis PharmaAugust 8, 2025 | marketbeat.comNuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPSAugust 6, 2025 | marketbeat.comNuvectis (NVCT) Q2 Loss Widens 43%August 5, 2025 | fool.comHC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $10.00August 5, 2025 | marketbeat.comNuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 5, 2025 | globenewswire.comFY2027 EPS Estimate for Nuvectis Pharma Reduced by AnalystAugust 2, 2025 | marketbeat.comNuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation StudyJuly 31, 2025 | globenewswire.comNuvectis Pharma Insiders Added US$2.50m Of Stock To Their HoldingsJuly 29, 2025 | finance.yahoo.comNuvectis Pharma Inc News (NVCT) - Investing.comJuly 18, 2025 | investing.comNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading TherapiesJuly 8, 2025 | finance.yahoo.comMarlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 25, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of StockJune 21, 2025 | insidertrades.comInsiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchasesJune 18, 2025 | finance.yahoo.comNuvectis Pharma: Still Interesting, But Still Too Risky To Jump InJune 18, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Realty Income Rallies Post-Earnings Miss—Here’s What Drove ItBy Gabriel Osorio-Mazilli | August 7, 2025ATHE, IMRX, NVCT, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$8.44 +0.22 (+2.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.45 +0.01 (+0.12%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Alterity Therapeutics NASDAQ:ATHE$4.94 -0.08 (-1.59%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.00 +0.05 (+1.11%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Immuneering NASDAQ:IMRX$5.75 +0.15 (+2.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.68 -0.07 (-1.13%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Nuvectis Pharma NASDAQ:NVCT$6.56 +0.03 (+0.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.56 0.00 (-0.08%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
